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Abstract
Introduction: Every year, HIV-associated tuberculosis (TB) deprives 350,000 mainly young people of productive and healthy lives.
People die because TB is not diagnosed and treated in those with known HIV infection and HIV infection is not diagnosed
in those with TB. Even in those in whom both HIV and TB are diagnosed and treated, this often happens far too late. These
deficiencies can be addressed through the application of new scientific evidence and diagnostic tools.
Discussion: A strategy of starting antiretroviral therapy (ART) early in the course of HIV infection has the potential to
considerably reduce both individual and community burden of TB and needs urgent evaluation for efficacy, feasibility and
broader social and economic impact. Isoniazid preventive therapy can reduce the risk of TB and, if given strategically in addition
to ART, provides synergistic benefit. Intensified TB screening as part of the ‘‘Three I’s’’ strategy should be conducted at every
clinic, home or community-based attendance using a symptoms-based algorithm, and new diagnostic tools should increasingly
be used to confirm or refute TB diagnoses. Until such time when more sensitive and specific TB diagnostic assays are widely
available, bolder approaches such as empirical anti-TB treatment need to be considered and evaluated. Patients with suspected
or diagnosed TB must be screened for HIV and given cotrimoxazole preventive therapy and ART if HIV-positive. Three large
randomized trials provide conclusive evidence that ART initiated within two to four weeks of start of anti-TB treatment saves
lives, particularly in those with severe immunosuppression. The key to ensuring that these collaborative activities are delivered
is the co-location and integration of TB and HIV services within the health system and the community.
Conclusions: Progress towards reducing HIV-associated TB deaths can be achieved through attention to simple and
deliverable actions on the ground.
John Donne, Meditation XVII, Devotions upon Emergent Occasions:
...any mans death diminishes me because I am involved in Mankinde; And therefore never send to know for whom the bell tolls;
it tolls for thee ....
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Introduction
In 2010, an estimated 34 million adults and children were
living with HIV/AIDS [persons living with HIV (PLHIV)] world-
wide: 1.1 million had HIV-associated tuberculosis (TB) and
350,000 with HIV-associated TB died [1]. Given that TB
is a curable disease and that HIV/AIDS can now be treated,
albeit with life-long drug therapy, why did this high mortality
occur? People died for three main reasons: (i) TB was not
diagnosed in those known to have HIV infection and who
were accessing antiretroviral therapy (ART); (ii) HIV was not
diagnosed in those with TB and therefore these patients
were not offered HIV care and treatment, and (iii) when the
two diseases were diagnosed and treated, these interven-
tions happened far too late. The application of new scientific
evidence and strategic use of new diagnostic tools make it
possible to address these gaps and dramatically reduce the
mortality caused by HIV-associated TB.
Discussion
Epidemiology
In 2010, 82% of the global burden of HIV-associated TB and
71% of the associated deaths occurred in sub-Saharan Africa,
with 10 countries in the southern region of Africa accounting
for more than 50% of cases [1]. Although HIV-associated TB
is a global problem, other focal points are South Asia
(India,Thailand, Indonesia and Myanmar) and Eastern Europe
(Ukraine and the Russian Federation) where intravenous
drug use drives the co-epidemic.
The scale up of ART over the last seven years has been a
remarkable, and deservedly applauded, success, with over
6.6 million people (5.1 million in sub-Saharan Africa)
estimated to be receiving treatment in low- and middle-
income countries [2]. However, between 8% and 26% of
patients die in the first year of treatment [3], and both
diagnosed and undiagnosed TB are recognized as major
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1causes of this mortality. Autopsy studies conducted in sub-
Saharan Africa before and during the ART era in adult HIV-
infected hospitalized patients found that TB, particularly
disseminated disease, was responsible for 40% to 50% of
deaths (Table 1) [47]. A more recent study in South Africa
in HIV-positive adults also showed that high proportion of
patients who died in the first six months of receiving ART had
disseminated TB [8].
Similarly, TB patients diagnosed with HIV and not receiving
HIV treatment have a high case fatality, which occurs early
during the course of anti-TB treatment [9], is generally higher
in smear-negative TB [10] and increases as the CD4 count
decreases (Table 2) [1,11,12]. Early diagnosis, treatment and
prevention of TB in PLHIV and early diagnosis and treatment
of HIV in TB patients are essential if these deaths are to be
avoided [13].
The 2012 WHO policy on collaborative TB/HIV activities
In March 2012, the World Health Organization (WHO)
released an updated policy on collaborative TB/HIV activities,
which consolidates evidence collated over the last six years
from randomized controlled trials, observational studies,
operational research and best practices from programme
implementation [14]. It follows the same framework as the
2004 interim policy document [15], structuring 12 activities
under three distinct objectives (Table 3), but with some
important differences. These include (i) recognition of the
crucial role of early ART initiation in preventing TB in PLHIV,
(ii) expanded use of HIV testing and HIV prevention to
include patients with presumptive TB as well as partners and
family members of patients with TB and (iii) more guidance
for the integration of HIV and TB services in time and place
and with other health programmes.
It is estimated that one million lives have been saved
between 2005 and 2010 as a result of implementing key
activities of the 2004 interim policy [16], and adoption of the
new policy should bring even greater benefit. Five important
spheres of work are needed to reduce HIV-TB mortality: (i)
preventing TB in PLHIV by early ART and isoniazid preventive
therapy (IPT); (ii) finding, diagnosing and treating tubercu-
losis in PLHIV; (iii) diagnosing and treating HIV in people with
presumptive and diagnosed TB, including drug-resistant TB;
(iv) addressing these challenges in children; and (v) ensuring
that HIV/TB services are co-located and/or integrated within
health facilities and the community.
Preventing TB in PLHIV: early ART and IPT
Antiretroviral therapy
There is now compelling evidence that ART is a powerful
preventive agent for TB in PLHIV. A systematic review and
meta-analysis of studies in cohorts of PLHIV from around the
world have shown that ART significantly reduces rates of TB,
with effects most apparent in patients with more advanced
HIV-disease or with the lowest CD4 counts (Table 4) [17].
At the individual level, these beneficial effects increase with
length of time on ART, although they never decrease to a
level that approaches the rates of TB seen in patients without
HIV-infection [18,19]. At the programme level, it has also
been shown in rural Malawi [20] and Cape Town, South Africa
[21], that when ART coverage in a population reaches a high
level of coverage, TB notification rates in that population
decrease, and in Malawi, this reduction was noted for both
new and recurrent TB (Table 5) [20].
Definitive evidence of the protective effect of ART at
higher baseline CD4 counts is provided in randomized
controlled trials. In a study in Haiti,TB incidence was reduced
by 50% in patients starting ART at CD4 counts between 200
and 350 cells/mL compared with those starting ART when
the CD4 count dropped to below 200 cells/mL or when
treatment was deferred until the onset of AIDS [22]. This
reduction in TB incidence was matched by a 75% reduction
in the risk of death for those starting ART early. These
data informed the 2010 revision of the WHO ART Guidelines
[23] that recommend starting ART at CD4 countsB350 cells/
mL. Evidence for the TB protective effect of ART at even
higher CD4 counts came from a recent HIV Prevention Trials
Network (HPTN 052) study [24] in which there was a 40%
reduction in serious HIV-related clinical events or death in
PLHIV starting ART at CD4 counts from 350 to 550 cells/mL
compared with those initiating ART at CD4 counts5250
cells/mL or when AIDS had developed. The difference in inci-
dence of clinical events was driven mainly by extrapulmonary
TB (EPTB), which developed in three patients in the early-
therapy group and 17 in the delayed-therapy group.
Mathematical models predict the enormous benefit
that early ART initiation might have on TB prevention [25].
Table 1. Causes of death in HIV-infected patients on medical wards  autopsy studies from sub-Saharan Africa
Country
Condition and/or diagnosis
at death
Number with
autopsies
Number (%) with TB
found at autopsy
Number (%) with
disseminated TB
Cote d’Ivoire [4] HIV wasting syndrome
diagnosed on medical wards
93 41 (44) 41 (44)
Kenya [5] HIV-positive diagnosed on
medical wards
75 38 (51) 31 (41)
Botswana [6] HIV-positive diagnosed on
medical wards
104 42 (40) 37 (36)
South Africa [7] HIV-positive diagnosed on
medical wards
96 40 (42) No data
TB, tuberculosis.
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2In a model using data from the South African HIV/AIDS
epidemic, universal and annual HIV testing of adults linked
to immediate start of ART in those HIV-positive could lead to
a halving in incidence of HIV-associated TB within five years
and a reduction by 95% within 40 years [26]. The strategy
works in two ways: a direct effect for the individual through
immune reconstitution and an indirect effect for the com-
munity by reducing HIV transmission, resulting in fewer
people infected with HIV and, therefore, being at risk of HIV-
associated TB.
Identification of HIV infection early in the course of disease
when CD4 counts are still high is essential for maximizing
the protective effect of ART for TB. In sub-Saharan Africa,
most patients are diagnosed with HIV and start ART at low
CD4 counts of 100 to 150 cells/mL, while the majority of HIV-
associated TB patients are diagnosed at higher CD4 counts
of 150 to 200 cells/mL [13,18]. Thus, HIV diagnosis and
initiation of ARTare generally too late to prevent TB, and the
TB preventive role of ART is largely squandered. Further and
urgent research is now needed to assess efficacy, feasibility,
safety, cost, social and population uptake and effect of the
‘‘Test and Treat’’ approach where the linkage of HIV testing
to CD4 count measurements, a barrier to ART access in
many low-income countries, is removed. Several randomized
controlled trials are underway [27], and in some countries
like Malawi, the strategy is already being implemented at
country level for pregnant women [28].
Isoniazid preventive therapy
IPT is another essential intervention for TB prevention. Given
daily for six months, it reduces the overall risk of TB in PLHIV
by 33%, with the protective effect confined to those with a
positive tuberculin skin test (TST) in whom the risk reduc-
tion is 64% [29]. Based on this evidence, WHO guidelines
between 1998 and 2009 emphasized that IPT should be used
as prophylaxis in PLHIV who are TST-positive [30].
However, implementation has been poor with the two
major stumbling blocks being the process of TST assess-
ment and reliable exclusion of active TB. To overcome this
inertia, the revised WHO IPT guidelines made a strong ex-
plicit recommendation that ‘‘TST is not a requirement for
initiating IPT in people living with HIV’’ although it ‘‘can be
used where feasible’’ [31]. Implementation is improving,
and by the end of 2010, about one-quarter of PLHIV enrolled
Table 2. Case fatality in HIV-infected smear-positive pulmonary TB patients before the era of antiretroviral therapy
Mortality rates at different CD4 counts (cells/mL)
in HIV-positive PTB patients
Country B200 200 to 499 500 or  HIV-negative PTB patients
Zaire at 24 months [11] 67% 22% 8%  2%
Cote d’Ivoire at 6 months [12] 10% 4% 3% B1%
PTB, pulmonary tuberculosis.
Table 3. WHO policy on recommended collaborative TB/HIV activities, 2012
A. Establish and strengthen the mechanisms for delivering integrated TB and HIV services
A.1. Set up and strengthen a coordinating body for collaborative TB/HIV activities functional at all levels
A.2. Determine HIV prevalence among TB patients and TB prevalence among people living with HIV
A.3. Carry out joint TB/HIV planning to integrate the delivery of TB and HIV services
A.4. Monitor and evaluate collaborative TB/HIV activities
B. Reduce the burden of TB in people living with HIV and initiate early antiretroviral therapy (the Three I’s for HIV/TB)
B.1. Intensify TB case-finding and ensure high quality antituberculosis treatment
B.2. Initiate TB prevention with isoniazid preventive therapy and early antiretroviral therapy
B.3. Ensure control of TB infection control in healthcare facilities and congregate settings
C. Reduce the burden of HIV in patients with presumptive and diagnosed TB
C.1. Provide HIV testing and counselling to patients with presumptive and diagnosed TB
C.2. Provide HIV prevention interventions for patients with presumptive and diagnosed TB
C.3. Provide cotrimoxazole preventive therapy for TB patients living with HIV
C.4. Ensure HIV prevention interventions, treatment and care for TB patients living with HIV
C.5. Provide antiretroviral therapy for TB patients living with HIV
TB, tuberculosis.
Adapted from Ref. [14].
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3in care and eligible for IPT on the basis of negative symptom
screening were started on TB preventive therapy [1].
The duration of treatment is currently recommended for
at least six months [31]. New data on the optimal duration
of IPT could improve the overall effectiveness of this
intervention, although this will raise additional challenges
for IPT delivery. In Botswana, 36 months of IPT reduced
TB incidence by 43% compared with six months of IPT,
the effects again being most apparent in TST-positive per-
sons [32]. After cessation of IPT, TB incidence increased
[33], even in the presence of ART, suggesting that con-
tinued isoniazid in these settings with high TB burden and
transmission is necessary to maintain a TB preventive effect.
Based on these and other data, the new WHO Guidelines
recommend that, in countries with high rates of community
TB transmission, such as in southern Africa, consideration
should be given to extended treatment for 36 months
or longer [31], and evidence is beginning to suggest that
IPT should be life long.
An area of ongoing research and debate is the optimal
timing and use of IPT and ART. Observational studies from
Brazil [34] and South Africa [35] and the data from Botswana
[32] suggest that sequential or concurrent use of ARTand IPT
results in a synergistic decline in risk of active TB. Rando-
mized placebo-controlled data regarding the additive bene-
ficial effects of this combined approach are awaited from
the ANRS TEMPRANO trial in Core d’Ivoire [NCT00495651]
and the HAART-IPT trial in South Africa [NCT00463086] [27].
However, in the interim and within the structured set up
of an ART clinic, an implementable strategy could be the
introduction and continuation of IPTonce patients are stable,
asymptomatic and prevalent TB has been unmasked [36].
Finding, diagnosing and treating TB in PLHIV
Intensified TB case finding
Linked to the prevention of TB with use of IPT is the need
to reliably find and diagnose active TB disease, and this
is packaged together under the acronym ‘‘The Three I’s’’
(intensified case finding, isoniazid preventive therapy and
infection control). Good progress has been made with
intensified TB case finding (ICF) in terms of the development
of a standardized screening tool [37] and indicators for
monitoring progress [38]. A standardized screening tool,
developed as a result of meta-analysis of available data,
focusses on four key questions: current cough of any duration
and a history of unintentional weight loss, night sweats
and fever in the last four weeks [37]. This is being used in
the field, and for example, in one study amongst HIV-infected
pregnant women, these questions were found to be accept-
able, feasible and associated with a high negative predic-
tive value [39]. In patient groups with the very highest TB
prevalence rates exceeding 10%, the negative predictive
value would be somewhat lower.
Available data show that about 50% of PLHIV being
screened have one or more positive symptoms, and 10% of
those with a positive screen may be subsequently diagnosed
with TB [37], with the numbers needed to screen and the
yield of active TB being dependent on prevalence of endemic
TB, the setting and the diagnostic methods used [40]. A small
proportion (1% to 2%) of asymptomatic PLHIV have micro-
biologically confirmed TB [37], although between 50% and
75% of such patients develop symptoms over the subsequent
few months [41,42].
These findings have implications for the programme
setting. In 2010, an estimated 2.3 million PLHIV (58% of
those enrolled in care) were screened for TB [1]. With the
new and simpler screening recommendations, these numbers
will undoubtedly increase. Symptom screening must be done
at baseline in all PLHIV attending pre-ART or ART clinics.
Screening should also not be a one-off event but performed
serially when PLHIV come to the clinic to prevent the small
proportion of asymptomatic patients with TB from slipping
through the net as well as to detect the high ongoing
incidence of new disease that persists long-term during ART.
Table 4. Reduction in the incidence rate ratio of TB in people
living with HIV and started on ART
Baseline CD4 count at the
time of starting ART
TB incidence rate ratio
(95% confidence intervals)
Less than 200 cells/mL 0.16 (0.07 to 0.36)
200 to 350 cells/mL 0.34 (0.19 to 0.60)
More than 350 cells/mL 0.43 (0.30 to 0.63)
Any CD4 count 0.35 (0.28 to 0.44)
TB, tuberculosis; ART, antiretroviral therapy.
Adapted from Ref. [17]: in the systematic review, data were
abstracted from 11 studies that met the inclusion criteria of the
systematic review  the intervention was ART, the comparator was
no ARV drugs and the outcome was an incident case of TB.
Table 5. Effect of ART scale up on TB case notification rates in a rural district, Malawi
Year Population Thyolo District, Malawi PLHIV ever started on ART New TB cases per 100,000 Recurrent TB cases per 100,000
2004 539,610 1550 253 18
2005 556,700 3145 259 20
2006 574,384 6216 255 20
2007 592,630 11,525 227 18
2008 611,424 16,106 191 14
2009 630,756 21,064 173 15
PLHIV, people living with HIV; ART, antiretroviral therapy; TB, tuberculosis.
Adapted from Ref. [20].
Harries AD et al. Journal of the International AIDS Society 2012, 15:17396
http://www.jiasociety.org/index.php/jias/article/view/17396 | http://dx.doi.org/10.7448/IAS.15.2.17396
4In the busy, understaffed ART clinics of sub-Saharan Africa,
it is important to address simple operational questions about
how often and when best to do this symptom screening so
as not to overwhelm the already high workload. Laboratory
capacity and appropriate quality assurance must also develop
in parallel to manage the increase in referrals.
The usual method of investigating for TB is with sputum
smear microscopy followed by chest radiography in those
with negative sputum smears. While this system has been
the mainstay for TB diagnosis for years, it is time consuming,
costly for the patient who needs to make multiple journeys
to the clinic and diagnostically insensitive [43,44]. This is
especially true for HIV-infected TB patients in whom a sig-
nificant proportion have negative sputum smears and a
normal chest x-ray at very low CD4 countsB50 cells/mL [45].
Without facilities for culture of Mycobacterium tuberculosis
(MTB), and this is the case in most resource-poor settings,
it is easy to miss the diagnosis of TB. There is an urgent need
for more accurate, inexpensive, quick point-of-care tests for
diagnosing TB.
The most important and revolutionary diagnostic develop-
ment to date is a sensitive and specific fully automated and
commercially available nucleic acid amplification test, the
Xpert MTB/RIF assay (Cepheid, Inc., Sunnyvale, CA, USA) for
use with sputum and other body specimens [46]. Xpert MTB/
RIF uses a common platform to detect TB and rifampicin
resistance. The cartridge-based system dispenses with the
need for prior sputum processing, requires minimal labora-
tory expertise and results are provided in an automated
manner in less than two hours. Sensitivity for one sputum
specimen for smear-positive PTB is high at 98%, and for
smear-negative PTB in whom sputum bacillary numbers
are low, sensitivities are 72%, 85% and 90% for one, two or
three specimens, respectively [46]. When used to investigate
suspected EPTB using samples from a wide range of anatomic
locations, Xpert MTB/RIF provides a rapid TB diagnosis in
over two-thirds of cases but with a wide range of sensitivity
(25% to 97%). Sensitivity is notably lower from body fluids
in which mycobacterial load is likely to be very low such as
pleural, pericardial and peritoneal fluid [47].
In December 2010, WHO strongly recommended that
Xpert MTB/RIF be used as the initial diagnostic test in
persons suspected of HIV-associated TB. By early 2012, over
450 Xpert instruments had been placed in 47 countries,
and work is ongoing to assess feasibility, accuracy and
effectiveness at district and sub-district health facilities
[48].The machine’s functionality in these settings will depend
on various operational factors that include cost, tempera-
tures, shelf-life of cartridges, electricity supplies, mainte-
nance and the need for annual calibration of the machine.
The machine’s impact will depend on how effective and
timely is the linkage between the patient, the diagnosis
and subsequent treatment. Data from South Africa illustrate
that, when the technology is separated from the patient
because of distance or related factors, the resulting gap
significantly undermines the potential to improve patient
outcomes [49].
Another promising test that might be useful in se-
vere immune suppression, which is often associated with
disseminated MTB, is the measurement of urine lipoarabi-
nomannan (LAM), one of the cell wall lipopolysaccharide
components of MTB. This can be measured either with an
ELISA or more easily with a Determine TB-LAM test strip
(Alere, Waltham, MA, USA), the latter costing $3.50 per test
strip and producing a result in 30 minutes.This offers the real
possibility of point-of-care testing. In HIV-infected patients,
specificity is high at over 95% for all CD4 strata. Useful
sensitivity is observed in those with CD4 countsB200 cells/
mL, but progressively increases as the CD4 count decreases,
reaching over two-thirds in those with CD4 countsB50 to
100 cells/mL [50,51].
Further work will determine the most feasible screening
and diagnostic algorithm for PLHIV in these clinic settings.
This will most probably be a combination of tests that include
sputum smears (to identify those with infectious TB), urine
LAM (to identify TB patients with the most advanced immune
suppression) and Xpert MTB/RIF, for which operational
research is urgently needed to determine how far periph-
erally the test can be decentralized to bring it as close to
the patient as possible. Accurate and timely diagnosis of TB
in the setting of HIV clinics has, and continues to be, the
Achilles heel of the Three I’s where it is important not only
to diagnose and treat TB but also exclude TB so that TB
preventive therapy can be safely implemented.
Empirical anti-TB treatment
Faced with the currentdifficulties of implementing ICFand IPT
and of diagnosing TB in PLHIV with low CD4 counts, it is
reasonable to consider the option of empirical anti-TB
treatment in high HIV-TB burden settings [52]. The rationale
isthatasthe CD4 count decreases,the riskof TB exponentially
increases, and at a certain point, there is more to gain than
lose in treating empirically for TB (Table 6). Two randomized
controlled trials [PROMPT (NCT01417988) and REMEMBER
(NCT01380080)] [27] are currently underway to test whether
this strategy has a high benefit-to-risk ratio in PLHIV about
to start ART and whether the intervention is associated with
a reduction in early and long-term mortality. A final caveat
is that empirical anti-TB treatment in settings where drug
resistance is high adds complexity to this approach and to
subsequent research study designs if the two trials underway
show positive benefit.
Diagnosing and treating HIV in patients with diagnosed
and presumptive TB
If we failto prevent TB,it is importantthatPLHIV who develop
active TB are diagnosed and treated for HIV/AIDS. The key
interventions include the use of cotrimoxazole preventive
therapy (CPT) and ART, provided early and promptly in the
course of anti-TB treatment. CPT is safe, cheap, easy to
administer and associated with significant decreases in
mortality of between 25% and 46% [5358]. CPT can also
be used before and in combination with ART, with observa-
tional and clinical studies showing 40% reductions in early
mortality and overall increases in life expectancy [5961].
ART is essential to the prognosis of patients with HIV-
associated TB: mortality risk is reduced by 64% and 95%,
there are excellent immunological/virological responses and
a reduction in recurrent TB [6264].
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5The management algorithm is straightforward (Figure 1),
and provider-initiated HIV testing and counseling (PITC), CPT
and ART are the basic standard of care.
Provider-initiated HIV testing and counselling
The HIV test is the gateway to HIV care and treatment.
It establishes the diagnosis and is an important component
of efforts to prevent HIV transmission. WHO recommends
that PITC is provided on a routine basis [65], and this
service, delivered largely through point-of-care HIV diagnos-
tics using dipstick technology, is feasible and acceptable in
most settings [66,67]. Good progress has been made in the
HIV testing of TB patients, with the proportion of new and
retreatment TB cases HIV tested rising from less than 5% in
2004 to 34% in 2010 [1]. Some regions do better than others
 in 2010, HIV testing reached 59% of notified TB cases in
Africa and 80% in Europe [1].
Two additional issues merit comment. First, in the routine
programme setting, false-positive and false-negative HIV test
results occur, and programmes need to decide on whether
they do serial or parallel testing, the need for confirmatory
tests and how to implement quality assurance. Second,
studies in East Africa, Guinea-Bissau and Zimbabwe [6871]
indicate the importance of moving HIV testing upstream to
include patients with suspected TB and ensuring that
those who are smear-negative can be referred for HIV care
and consideration of ART. In Zimbabwe, 63% of patients
suspected of PTB who were found to be smear-negative were
HIV-positive and the majority had CD4 cell countsB350
cells/mL [71]. During 12-month follow-up, 18% were diag-
nosed as having TB, only 15% were started on ART and
12% of the cohort was known to have died. In line with new
WHO recommendations [14], these poor outcomes could
be avoided if patients with suspected TB, and this applies to
partners and family members, were routinely HIV tested
and those found HIV-positive linked to structured HIV care
and treatment that included TB screening.
Antiretroviral therapy
ART is an essential intervention for the management of
HIV-associated TB. The Starting Antiretroviral Therapy at
Three Points in Tuberculosis (SAPIT) trial clearly showed
that across a range of CD4 counts it was better to start
ART during anti-TB treatment than to wait until TB treat-
ment had been completed [72], and these data informed the
2010 WHO ART guidelines recommending that all HIV-
positive TB patients are eligible for ART, regardless of CD4
count [23].
The issue of optimal timing of ART in relation to start of
anti-TB treatment has been clarified by three randomized
controlled studies: CAMELIA, STRIDE and SAPIT [7375].
While all three trials were slightly different  median CD4
counts at baseline ranged from 25 cells/mL in Cambodia to
150 cells/mL in South Africa, and there were different
working definitions of TB  collectively, one clear message
emerges, namely that earlier initiation of ART saves lives in
HIV-infected patients with TB. These benefits were particu-
larly evident for those with CD4 cell countsB50 cells/mL
in whom the risk of HIV infection or death was minimized
by starting ART within the first two to four weeks of TB
treatment. These and subsequent studies [76,77] show that
Provider initiated HIV testing and counselling 
[PITC]
If HIV-seropositive
Start cotrimoxazole preventive therapy as soon as possible
Start antiretroviral therapy within
the first 2–8 weeks of TB treatment
Figure 1. Management algorithm for HIV-associated TB.
Table 6. Potential benefits from empirical antituberculosis treatment in persons living with HIV who are severely immune
suppressed
Benefit Explanation
Mortality reduction   Treatment of active, undiagnosed TB
  Treatment through rifampicin of drug-susceptible gram-positive bacterial sepsis
TB prevention   6-months treatment of Mycobacterium tuberculosis in those with latent TB infection
  6-months prevention of exogenous TB infection in those with no latent infection
Reduced nosocomial TB transmission   Treatment of active, undiagnosed TB, which is therefore not transmitted
  Prevention of exogenous TB infection in those who might be exposed
Promotion of integrated HIV-TB care   TB treatment and ART provided either in same clinic or in different clinics within the
same health facility
Reducing the diagnostic dilemma of
diagnosing and excluding TB
  Empirical treatment provides effective treatment to all those with active TB and
prevents TB in all those with no active TB who could benefit from IPT
TB, tuberculosis; ART, antiretroviral therapy; IPT, isoniazid preventive therapy.
Adapted from Ref. [52].
Harries AD et al. Journal of the International AIDS Society 2012, 15:17396
http://www.jiasociety.org/index.php/jias/article/view/17396 | http://dx.doi.org/10.7448/IAS.15.2.17396
6the risk of immune reconstitution inflammatory syndrome
(IRIS) is increased, especially in those with low CD4 counts,
but this is counterbalanced by improved survival. One
exception is in HIV-infected patients with TB meningitis in
whom early ART is not associated with improved survival,
probably because of the devastating effects of IRIS within
the confined space of the central nervous system [78].
In many low-income countries, CD4 count testing remains
an obstacle to accessing HIV care and treatment, and
insistence on its use will reduce ART uptake. However, where
facilities for measurement do exist, knowledge of the CD4
count would allow a more rational guide as to whether ART
is started within two weeks or between two and eight weeks
of the start of anti-TB treatment.
There are no important drug-drug interactions between
first-line ART and standard anti-TB treatment, provided
efavirenz is used as the non-nucleoside reverse transcriptase
inhibitor. However, protease inhibitors, used in most second-
line ART regimens, cannot be administered with rifampicin.
Rifabutin has minimal effects on serum levels of protease
inhibitors and is therefore a potentially safe and effective
agent to maintain rifamycin-based anti-TB treatment with
second-lineART[79].Todate,however,issuessuchascost,lack
offixed-dosecombinationpillsandlackofregistrationinmany
countries preclude its use in current routine management.
ART and drug-resistant TB
In the absence of ART, HIV-infected patients with multidrug-
resistant TB (MDR-TB) and extensively drug-resistant TB
(XDR-TB) have high case fatality rates [8082]. With the
rollout of Xpert MTB/RIF assay as the recommended
diagnostic test in HIV-infected patients with suspected TB,
it is likely that the number of patients diagnosed with MDR-
TB will increase dramatically.The earlier detection of MDR-TB
should in itself improve prognosis provided there is ready
access to appropriate second-line anti-TB treatment, as most
MDR-TB patients in low-income countries are diagnosed late,
usually only when they fail or relapse on standard anti-TB
treatment.
Observational cohort studies have shown that ART im-
proves survival of HIV-infected patients with MDR-TB [83]
and XDR-TB [84], and ART should be started as early as
possible in combination with CPT [85]. Early ART com-
bined with often advanced clinical disease puts patients
at increased risk of TB-IRIS in addition to frequent drug
interactions and co-toxicities [86]. With promising new TB
drug compounds on the horizon to treat drug-sensitive and
drug-resistant TB, it will be essential to include patients
with HIV-associated TB in clinical trials to understand and
better manage the potential interactions between ART, CPT
and the new TB agents.
HIV-associated TB in women and children
In high HIV-prevalence settings, more women are notified
with TB compared with men, especially in the southern part
of Africa, and this is due to the feminization of the HIV epi-
demic in this region [87]. There appears to be no difference
in access, treatment or response to treatment between male
and female patients. TB in pregnant women living with HIV
increases the risk of vertical transmission of HIV and there
is a higher risk of maternal mortality in pregnant women co-
infected with HIV and TB compared with pregnant women
who just have TB [87].
Although TB is not the great killer in HIV-infected children
as it is in adults, it is nonetheless an important cause of
their death [88,89]. Because of overlap in clinical features
between children with HIV/AIDS and TB, accurate diagnosis
of HIV-associated TB is very difficult, even with point scoring
systems and diagnostic algorithms, which are anyway rarely
used in routine practice [87]. In general, the HIV-TB strategies
described for adults are equally applicable to children,
but some brief comments are in order.
ART is recommended for all children under the age of
two years with confirmed HIV infection, regardless of CD4
count [90], and under trial conditions, this is associated
with a significant reduction in mortality and disease progres-
sion, including a reduction in the burden of active TB [91].
However, despite ART, the risk of TB remains high. Primary
IPT in one trial in South Africa amongst children on ART failed
to reduce this risk or the risk of death [92], while amongst
young children not accessing ART, primary isoniazid prophy-
laxis in another South African trial was associated with
reduced TB incidence and death [93]. The conundrum of
how to best prevent TB in HIV-infected infants is still not
resolved. Scale up of ART in this population is slow and
requires far better access to early infant diagnosis and
appropriate paediatric ART formulations. BCG vaccination
in these children is potentially dangerous with an attendant
risk of local and disseminated TB [89], underscoring the
urgent need for a TB vaccine that can be safely given to
young children with HIV infection.
TB case finding and diagnosis in children is hampered
by the frequent failure to produce sputum and by a high
proportion presenting with EPTB. Within these constraints,
Xpert MTB/RIF is proving a potentially useful tool in children
for the diagnosis of PTB (using induced sputum specimens)
and EPTB [94], especially lymphadenitis [95].
Delivering HIV-TB services
Despite good progress made in HIV care and treatment for
TB patients only one third of notified TB patients in 2010
were HIV tested, and of those, only 46% received ART [1].
Co-location and/or integration of TB and ART services are
the key to achieving better and timely collaborative activities.
In a South African township, for example, only 11% of HIV-
infected patients with CD4 cell countsB50 cells/mL who
were referred from TB services to separate HIV services
started ART within four weeks of their TB diagnosis [96].
Centres for TB diagnosis and treatment and for HIV care and
treatment must be integrated, located together or better
matched quantitatively and geographically. HIV testing
and TB treatment services are already well decentralized in
many countries to peripheral sites, so the goal is now to
decentralize services for TB diagnosis and ART provision.
Innovative approaches are needed  for example, providing
comprehensive HIV-TB care and treatment at the TB clinic
for the duration of TB treatment with transfer to the HIV
programme after TB treatment is completed [97]. Atten-
tion must be paid to clinic infrastructure with good natural
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7cross-ventilation and patient-flow so as to minimize the risk
of TB nosocomial transmission.
Current screening and treatment strategies miss large
numbers of people who never make it to health facilities,
so it is essential to think out of the box and determine
whether community diagnostic, treatment and preventive
services can be provided through home-based and mobile
care teams. For example, in Malawi, oral self-testing for HIV
was acceptable and accurate and has the potential for high
uptake at community level if it can be supervised and linked
to counselling and care [98]. In Zambia, household-based
HIV and TB interventions offering HIV testing, easy access to
TB diagnosis and linkage to HIV-TB care and treatment
were feasible and reduced TB prevalence in the community
[99101]. In Zimbabwe, active TB case finding in the
community, particularly with a mobile van approach, was
successful in detecting and reducing community prevalence
of culture-positive TB [102]. In Thibela, South Africa,
community-wide IPT for nine months regardless of HIV
status in a gold-mining work force had no effect in reduc-
ing community-wide TB incidence or prevalence [103].
Moreover, any individual benefit in reducing TB risk among
those who received IPT was limited to the duration of
therapy [104], strengthening the argument for long-term
therapy when used in countries with high TB transmission
rates.
Not everyone identified and diagnosed through a com-
munity approach makes it to care, either for TB or HIV
treatment [105], so it is essential that these gaps are
plugged. As with case detection, integrated care and
treatment can also be given through a home-based approach
and may be associated with excellent treatment outcomes
[106].
Conclusions
In summary, new scientific evidence shows us what inter-
ventions can make a difference and we have new tools to
improve TB diagnosis. The job now is to apply this evidence
and these new tools within routine healthcare systems and
communities in resource-poor countries. Much earlier start
of ART combined with IPT, active TB case finding using
innovative TB diagnostic technology, quality assured HIV
testing of patients with confirmed or suspected TB and
timely initiation of CPT and ART to co-infected patients will
save many lives and may be augmented by bold initiatives
involving empirical TB treatment and community-based
interventions. The 2012 World TB statement of ‘‘Zero TB
deaths’’ fits well into the bold new vision articulated by
UNAIDS of the Three Zeros  zero new HIV infections, zero
discrimination and zero AIDS-related deaths [107]. Every
year, HIV-associated TB robs 350,000 young men and women
of a potentially long, healthy and productive life. As Bo
Draser, Editor of the Transactions of the Royal Society of
Tropical Medicine & Hygiene, once remarked ‘‘We need to
take death away from these young people and make it the
monopoly of the old’’ [108].
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